256
Views
1
CrossRef citations to date
0
Altmetric
ORIGINAL RESEARCH

Effects of Ultra-Long-Acting Insulin Compared to Long-Acting Insulin on Diabetic Ketoacidosis Incidence in Type 1 Diabetes Mellitus Patients

, , , ORCID Icon, & ORCID Icon
Pages 733-739 | Published online: 05 Mar 2022

References

  • American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2013;36(Supplement_1):S67–S74. doi:10.2337/dc13-S067
  • O’Keeffe DT, Maraka S, Rizza RA. HbA1c in the evaluation of diabetes mellitus. JAMA. 2016;315(6):605–606.
  • Desai D, Mehta D, Mathias P, Menon G, Schubart UK. Health care utilization and burden of diabetic ketoacidosis in the US over the past decade: a nationwide analysis. Diabetes Care. 2018;41(8):1631–1638.
  • Kitabchi AE, Umpierrez GE, Miles JM, Fisher JN. Hyperglycemic crises in adult patients with diabetes. Diabetes Care. 2009;32(7):1335–1343.
  • Zhong VW, Juhaeri J, Mayer-Davis EJ. Trends in hospital admission for diabetic ketoacidosis in adults with type 1 and type 2 diabetes in England, 1998–2013: a retrospective cohort study. Diabetes Care. 2018;41(9):1870–1877.
  • Flores M, Amir M, Ahmed R, et al. Causes of diabetic ketoacidosis among adults with type 1 diabetes mellitus: insulin pump users and non-users. BMJ Open Diabetes Res Care. 2020;8(2):e001329.
  • Barski L, Brandstaetter E, Sagy I, Jotkowitz A. Basal insulin for the management of diabetic ketoacidosis. Eur J Intern Med. 2018;47:14–16.
  • Woo VC. A review of the clinical efficacy and safety of insulin degludec and glargine 300 U/mL in the treatment of diabetes mellitus. Clin Ther. 2017;39(8S2):S12–S33.
  • Heise T, Kaplan K, Haahr HL. Day-to-day and within-day variability in glucose-lowering effect between insulin degludec and insulin glargine (100 U/mL and 300 U/mL): a comparison across studies. J Diabetes Sci Technol. 2018;12(2):356–363.
  • Heise T, Mathieu C. Impact of the mode of protraction of basal insulin therapies on their pharmacokinetic and pharmacodynamic properties and resulting clinical outcomes. Diabetes Obes Metab. 2017;19(1):3–12.
  • Thalange N, Deeb L, Iotova V, et al. Insulin degludec in combination with bolus insulin aspart is safe and effective in children and adolescents with type 1 diabetes. Pediatr Diabetes. 2015;16(3):164–176.
  • Pang T, Bain SC, Black RNA, et al. A multicentre, UK, retrospective, observational study to assess the effectiveness of insulin glargine 300 units/mL in treating people with type 1 diabetes mellitus in routine clinical practice (SPARTA). Diabet Med. 2019;36(1):110–119.
  • Ooi CP, Ting TH, Lye MS. Ultra‐long-acting insulin versus long-acting insulin for type 1 diabetes mellitus. Cochrane Database Syst Rev. 2018;2018(7):CD011102.
  • Seeger P, Gabrielsson A. Applicability of the Cochran Q test and the F test for statistical analysis of dichotomous data for dependent samples. Psychol Bull. 1968;69(4):269–277.
  • Joffe BI, Distiller LA. Diabetes mellitus and hypothyroidism: strange bedfellows or mutual companions? World J Diabetes. 2014;5(6):901–904.